Immunocore Q1 KIMMTRAK Sales Climb 13.6% to $106.7M with $845M Cash
IMCR•Immunocore posted Q1 net sales of $106.7 million for KIMMTRAK, up 13.6% year-over-year, and ended March 31 with $845 million in cash and securities, while net income rose to $13.0 million ($0.25 per share). Phase 3 data showed KIMMTRAK doubled five-year survival in metastatic uveal melanoma (16% vs 8%; HR0.67).
1. Q1 Financial Performance
Immunocore generated $106.7 million in KIMMTRAK net sales for Q1 2026, a 13.6% increase from $93.9 million a year earlier. R&D expenses rose to $61.1 million while SG&A fell to $37.9 million, resulting in net income of $13.0 million ($0.25 per diluted share) and ending the quarter with $844.9 million in cash and marketable securities.
2. KIMMTRAK Survival Data
Phase 3 trial results presented at AACR show KIMMTRAK doubled five-year overall survival in HLA-A*02:01 positive metastatic uveal melanoma, with an OS rate of 16% versus 8% in the control arm and a hazard ratio of 0.67. The median OS was 21.6 months compared to 16.9 months for investigator’s choice, with benefits regardless of tumor burden, LDH levels or tumor location.
3. Pipeline and Growth Opportunities
Immunocore is expanding KIMMTRAK into second-line and later advanced cutaneous melanoma through the TEBE-AM Phase 3 trial, with topline data expected in H2 2026, and into adjuvant uveal melanoma via an EORTC-backed trial. The company’s PRAME-targeted bispecific candidate brenetafusp is in a registrational Phase 3 trial for first-line advanced cutaneous melanoma and Phase 1/2 studies across multiple tumors.
